Ose Immunotherapeutics develops clinical-stage immunotherapies that either activate cytotoxic T‑cells against tumor neo‑epitopes, reprogram suppressive cells in the tumor microenvironment, or dampen effector T‑cell activity to promote regulatory tolerance for inflammatory diseases. Their three patented platforms generate first‑in‑class candidates that are advanced through Phase 1‑3 trials in partnership with pharma, biotech, and academic collaborators.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with cancer or immune‑mediated inflammatory diseases often lack therapies that can precisely activate anti‑tumor immunity or restore immune tolerance, leading to suboptimal outcomes and unmet medical needs.
Solution
Ose Immunotherapeutics creates clinical‑stage immunotherapies that modulate immune activation and regulation for both immuno‑oncology and immuno‑inflammation. The company leverages three patented pre‑clinical platforms to generate first‑in‑class agents that either stimulate cytotoxic T‑cell responses against tumor neo‑epitopes, re‑educate suppressive cells in the tumor microenvironment, or down‑regulate effector T cells to reduce pathological inflammation while enhancing regulatory T‑cell activity. Candidates are advanced through Phase 1‑3 trials either directly by Ose or in collaboration with pharmaceutical, clinical and academic partners, enabling rapid translation of novel immune‑modulating mechanisms into therapeutic options.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking novel immune‑modulating candidates, as well as clinical research groups focused on oncology and autoimmune disease therapeutics.
Features
- Three patented research platforms delivering first‑in‑class immunotherapy modalities
- T‑cell activation strategy using tumor‑specific neo‑epitopes to boost cytotoxic responses
- Approach to convert suppressive tumor‑microenvironment cells into functional effectors
- Immuno‑inflammatory pathway modulation that lowers effector T‑cell activity and raises regulatory T‑cell tolerance
- Clinical‑stage pipeline spanning oncology and autoimmune/inflammatory indications
- Flexible development model combining in‑house trials with strategic partnership collaborations